Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Resectable pancreatic ductal adenocarcinoma
Data

Cancers·Resectable pancreatic ductal adenocarcinoma

DataResectable pancreatic ductal adenocarcinoma

Back to the Resectable pancreatic ductal adenocarcinoma hub →73 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

73

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
KRAS G12C-mutant pancreatic ductal adenocarcinoma
Shares CA 19-9, Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel, Revolution Medicines and the tags subtype-page, gastrointestinal.
Cancer
KRAS wild-type pancreatic ductal adenocarcinoma
Shares Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel, FOLFIRINOX / mFOLFIRINOX, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Shares PRODIGE 24 / CCTG PA6, Whipple procedure (pancreaticoduodenectomy), Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), Lymphadenectomy (lymph node dissection), Ampullary cancer (ampulla of Vater), CT (computed tomography) and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares Lymphadenectomy (lymph node dissection), CT (computed tomography), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Localised anal squamous cell carcinoma (stage I to III)
Shares Chemoradiation (chemoradiotherapy, CRT), Robotic & minimally invasive surgery, Capecitabine, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Goblet cell adenocarcinoma of the appendix
Shares Lymphadenectomy (lymph node dissection), CT (computed tomography), Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Shares CT (computed tomography), KRAS and the tags subtype-page, gastrointestinal.

technologies

16

Biliary stenting and drainage CT (computed tomography)Cytotoxic chemotherapy Endoscopic ultrasound and EBUS systems Enhanced recovery (ERAS) and perioperative nutrition Germline (hereditary) testing High-risk pancreatic surveillance (CAPS / PRECEDE)Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)KRAS & RAS inhibitors Liquid biopsy (ctDNA)MRD / molecular residual disease testing Off-the-shelf cancer vaccines Personalised neoantigen (mRNA) vaccines Platinum agents Robotic & minimally invasive surgery Topoisomerase-I inhibitors (and ADC payloads)

targets

2

BRCA1 / BRCA2 (HRD)KRAS

drugs

7

Phase 2Personalised mRNA neoantigen vaccine

Autogene cevumeran

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

Phase 2Off-the-shelf lymph-node-targeted KRAS peptide vaccine

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

companies

6

BioNTech Dutch Pancreatic Cancer Group Eli Lilly (incl. Loxo)Elicio Therapeutics Revolution Medicines Roche / Genentech

pathways

2

Pancreatic cancer (KEGG map)RAS / RAF / MEK / ERK (MAPK)

terms

11

CA 19-9 Chemoradiation (chemoradiotherapy, CRT)Circulating tumour DNA (ctDNA)Germline BRCA mutation (gBRCA)Lymphadenectomy (lymph node dissection)Minimal / molecular residual disease (MRD)Neoadjuvant / adjuvant / perioperative Obstructive jaundice and biliary obstruction Resectable, borderline resectable and unresectable Resection margins (R0 / R1 / R2)Whipple procedure (pancreaticoduodenectomy)

trials

11

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC AMPLIFY-7P CEB-01 in Locally Resectable Pancreatic Cancer CONKO-001 ESPAC-3 ESPAC-4 NORPACT-1 PREOPANC-1 / PREOPANC-2 PRODIGE 24 / CCTG PA6 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

ideas

3

Four weeks of training and nutrition before major cancer surgery, as standard Personalised vaccines given only when the blood test turns positive RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable

people

6

Eileen M. O'Reilly Jürgen Weitz Marc G. Besselink Richard Schulick Thierry Conroy Vinod P. Balachandran

key papers

9

Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection ESPAC-4: adjuvant gemcitabine and capecitabine versus gemcitabine monotherapy in resected pancreatic cancer ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Add 11 pancreatic cancer subtype pages · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Resectable pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/resectable-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id resectable-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.